XKRX
068760
Market cap1.28bUSD
Oct 08, Last price
38,800.00KRW
1D
-3.24%
1Q
-5.37%
Jan 2017
62.34%
IPO
294.03%
Name
Celltrion Pharm Inc
Chart & performance
P/E
44.31
P/S
3.20
EPS
875.58
Div yield, %
0.52%
Shrs. gr., 5y
0.87%
Rev. gr., 5y
18.09%
Revenues
536.40b
+12.26%
Net income
38.75b
+76.42%
CFO
86.43b
+52.74%
Dividend
Dec 29, 2025204 KRW/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Celltrion Pharm Inc. operates as a South Korean pharmaceutical firm, specializing in the creation and distribution of biosimilar medications and over-the-counter (OTC) drugs. Its extensive product portfolio spans a multitude of therapeutic categories, encompassing treatments for conditions related to liver health, inflammation, allergies, respiratory and cardiovascular systems, digestion, hormonal and metabolic disorders, infectious diseases, immune responses, oncology, and general nutrition. The company supplies its pharmaceutical offerings to a diverse client base, including university hospitals and local pharmacies. Established in 1976, Celltrion Pharm Inc. is based in Cheongju, South Korea.
Key people
Myeong Geun Oh
Co-President · since 2023
Yeong Ho Yoo
Co-President, Chief Executive Officer, Director · since 2024
Seung Jae Choi
Vice President · since 2021
Chang Seon Lee
Managing Director · since 2022
Deok Gyu Choi
Assistant Managing Director · since 2022
Beom Seon Hong
Assistant Managing Director · since 2024
Yeong Seop Lee
Internal Auditor · since 2020
Byeong Gwan Moon
Assistant Managing Director · since 2024
Seong Jun Park
Assistant Managing Director · since 2024
Ji Seok Yang
Assistant Managing Director · since 2022
Co-Chairman · since 2023
Co-Chairman · since 2023
Non-Executive Independent Director · since 2023
Non-Executive Independent Director · since 2025
Tae Yeong Song
Non-Executive Independent Director · since 2021
Bong Hui Won
Non-Executive Independent Director · since 2023
Sang Wu Yang
Non-Executive Independent Director · since 2021
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||